文献速递贫血与红细胞疾病

开发用于非输血依赖型地中海贫血患者的患者报告结局症状测量工具(NTDT-PRO©)

Development of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO© ).
PubMed 文献 · Am J Hematol · 2018-11-26

本研究旨在开发符合美国食品药品监督管理局(FDA)要求的非输血依赖型地中海贫血(NTDT)慢性贫血症状患者报告结局工具NTDT-PRO©。通过来自黎巴嫩、希腊和加拿大3个中心的25例患者进行概念引出访谈生成9个条目,再经2个中心21例患者的认知访谈删除4个条目,最终NTDT-PRO包含6个条目,测量疲倦、无力和气短(伴或不伴体力活动)。

要点

  • NTDT-PRO是首个针对NTDT患者慢性贫血症状的疾病特异性患者报告结局工具。
  • 工具开发遵循FDA 2009年患者报告结局指南,经概念引出和认知访谈两阶段。
  • 最终工具含6个条目:疲倦、无力、气短(伴或不伴体力活动)。

核心结论

  • NTDT-PRO是基于FDA 2009年患者报告结局开发指南的严格方法学开发的新型疾病特异性健康相关生活质量工具,用于评估NTDT患者的慢性贫血症状。

研究设计与样本

  • 研究为患者报告结局工具开发研究,参与者中位年龄36岁(范围18-47岁),60%为女性。
  • 初始开发阶段对来自3个中心(黎巴嫩、希腊和加拿大)的25例患者进行概念引出访谈,生成9个条目纳入NTDT-PRO草案。
  • 随后对来自2个中心(黎巴嫩和希腊)的21例患者进行一轮认知访谈。

主要发现

  • 概念引出访谈和临床输入后生成9个条目纳入NTDT-PRO草案。
  • 认知访谈后从NTDT-PRO草案中删除4个条目:疼痛、头痛、注意力和苍白。
  • 最终NTDT-PRO包含6个条目,测量疲倦、无力和气短,伴或不伴体力活动。

关键数值与推荐

  • 最终NTDT-PRO包含6个条目:疲倦、无力、气短(伴或不伴体力活动)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

β-Thalassemia, a hereditary blood disorder caused by reduced or absent synthesis of the β-globin chain of hemoglobin, is characterized by ineffective erythropoiesis, and can manifest as nontransfusion-dependent thalassemia (NTDT) or transfusion-dependent thalassemia (TDT). Many patients with NTDT develop a wide range of serious complications that affect survival and quality of life (QoL). Patient-reported outcomes (PRO), including health-related QoL (HRQoL), are important tools for determining patient health impairment and selecting appropriate treatment. However, there are currently no disease-specific PRO tools available to assess symptoms related to chronic anemia experienced by patients with NTDT. This study aimed to develop a new, US Food and Drug Administration (FDA)-compliant PRO of chronic anemia symptoms, the NTDT-PRO© tool, for use in patients with NTDT. Participants had a median age of 36 years (range, 18-47) and 60% were female. The initial development of the NTDT-PRO tool involved concept-elicitation interviews with 25 patients from 3 centers (in Lebanon, Greece, and Canada); subsequent interview discussions and clinical input resulted in the generation of 9 items for inclusion in the draft NTDT-PRO. Following a round of cognitive interviews involving 21 patients from 2 centers (in Lebanon and Greece), 4 items (Pain, Headaches, Ability to Concentrate, and Paleness) were removed from the draft NTDT-PRO. The final NTDT-PRO comprises 6 items that measure Tiredness, Weakness, and Shortness of Breath, with or without Physical Activity. The NTDT-PRO is a new disease-specific HRQoL tool for patients with NTDT, developed using a thorough methodology based on FDA 2009 PRO development guidelines.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Taher A, Viprakasit V, Cappellini MD, et al. Development of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO© ). Am J Hematol. 2018. PMID: 30394579. doi:10.1002/ajh.25343

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。